Otolaryngology, Head & Neck Surgery, The Royal Melbourne Hospital City Campus, Parkville, Victoria, Australia.
Otolaryngology, Head & Neck Surgery, The Royal Melbourne Hospital City Campus, Parkville, Victoria, Australia
BMJ Case Rep. 2024 Jan 23;17(1):e258269. doi: 10.1136/bcr-2023-258269.
Primary small cell neuroendocrine carcinoma (SCNC) of the larynx is a rare subtype of laryngeal cancer, accounting for less than 1% of all laryngeal tumours. It most commonly affects smokers in their fifth to sixth decade of life and is characterised by a high incidence of advanced disease at presentation and an aggressive clinical course. Here we present a case of SCNC of the larynx, presenting initially with dysphonia, and an associated literature review collating current knowledge regarding therapeutic approaches. After review of 260 cases in the literature we determined a disease-specific survival of 33.1%. Combined chemoradiotherapy is currently the recommended first-line treatment option.
喉原发性小细胞神经内分泌癌(SCNC)是一种罕见的喉癌亚型,占所有喉肿瘤的比例不到 1%。它最常发生在 50 至 60 岁的吸烟者中,其特征是在出现时晚期疾病的发病率高,且临床病程具有侵袭性。在此,我们报告了一例喉 SCNC 病例,最初表现为声音嘶哑,并对目前有关治疗方法的知识进行了相关文献回顾。在对文献中的 260 例病例进行回顾后,我们确定了 33.1%的疾病特异性生存率。目前,联合放化疗是推荐的一线治疗选择。